Laboratory Model Reveals Genetic Risk Loci for AMD
|
By LabMedica International staff writers Posted on 20 May 2019 |

Image: A micrograph showing retinal cells derived from a patient\'s skin cells, via induced pluripotent stem cells. The cells are organized in a polygonal shape and have taken on characteristic pigmentation (Photo courtesy of the University of California, San Diego).
Eye disease researchers used advanced stem cell technology to create a laboratory model of age-related macular degeneration (AMD), which enabled in-depth analysis of the genetics underlying the syndrome.
AMD, one of the most common causes of vision loss in the elderly, causes the slow degradation of the cells comprising the macula of the retina, which is the region in the back of the eye that transmits information to the brain. The exact cause of the disease is unknown, but studies have suggested that genetics plays an important role.
To define the role of genetic risk in AMD, investigators at the University of California, San Diego (USA) created an in vitro model based on human induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) cells from six subjects. To do this, they generated iPSCs from skin cells, and then used a cocktail of molecules and growth factors to transform the iPSCs into retinal cells. The induced RPEs were found to have morphological and molecular characteristics similar to those of native RPE.
The model system was used to generate molecular data, including RNA transcripts and epigenetic information. These findings were combined with complementary published data from 18 adults with and without AMD.
Results revealed that the genetic variant most closely associated with AMD was rs943080, a specific genetic variation that affected expression of the VEGFA (vascular endothelial growth factor A) gene, possibly through regulation by a non-coding region of the genome. Five of the six participants had one copy of rs943080 and one person had two copies of the gene variant. VEGFA protein is known for supporting new blood vessel growth, a process that characterizes AMD.
"We did not start with the VEGFA gene when we went looking for genetic causes of AMD," said senior author Dr. Kelly A. Frazer, professor of pediatrics at the University of California, San Diego. "But we were surprised to find that, with samples from just six people, this genetic variation clearly emerged as a causal factor."
The authors concluded that their results had established a molecular hypothesis for the VEGFA genetic risk locus in AMD and illustrated the potential of iPSC-RPE as a model system to study the molecular function of genetic variation associated with AMD.
The AMD stem cell study was published in the May 9, 2019, online edition of the journal Stem Cell Reports.
Related Links:
University of California, San Diego
AMD, one of the most common causes of vision loss in the elderly, causes the slow degradation of the cells comprising the macula of the retina, which is the region in the back of the eye that transmits information to the brain. The exact cause of the disease is unknown, but studies have suggested that genetics plays an important role.
To define the role of genetic risk in AMD, investigators at the University of California, San Diego (USA) created an in vitro model based on human induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) cells from six subjects. To do this, they generated iPSCs from skin cells, and then used a cocktail of molecules and growth factors to transform the iPSCs into retinal cells. The induced RPEs were found to have morphological and molecular characteristics similar to those of native RPE.
The model system was used to generate molecular data, including RNA transcripts and epigenetic information. These findings were combined with complementary published data from 18 adults with and without AMD.
Results revealed that the genetic variant most closely associated with AMD was rs943080, a specific genetic variation that affected expression of the VEGFA (vascular endothelial growth factor A) gene, possibly through regulation by a non-coding region of the genome. Five of the six participants had one copy of rs943080 and one person had two copies of the gene variant. VEGFA protein is known for supporting new blood vessel growth, a process that characterizes AMD.
"We did not start with the VEGFA gene when we went looking for genetic causes of AMD," said senior author Dr. Kelly A. Frazer, professor of pediatrics at the University of California, San Diego. "But we were surprised to find that, with samples from just six people, this genetic variation clearly emerged as a causal factor."
The authors concluded that their results had established a molecular hypothesis for the VEGFA genetic risk locus in AMD and illustrated the potential of iPSC-RPE as a model system to study the molecular function of genetic variation associated with AMD.
The AMD stem cell study was published in the May 9, 2019, online edition of the journal Stem Cell Reports.
Related Links:
University of California, San Diego
Latest BioResearch News
- Inherited Genetic Differences Help Explain Variable CAR T-Cell Therapy Outcomes
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








